COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

21 Mar 2023 07:00:32 By Nasdaq GlobeNewswire

UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 Mar 2023 11:18:55 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 Mar 2023 06:30:53 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

15 Mar 2023 06:30:16 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

07 Mar 2023 07:00:13 By Nasdaq GlobeNewswire

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

22 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia

21 Feb 2023 06:30:49 By Nasdaq GlobeNewswire

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

09 Feb 2023 07:00:38 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

22 Dec 2022 07:00:46 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

21 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

15 Dec 2022 07:00:42 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

01 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series

21 Nov 2022 07:00:33 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Closing of Public Offering

15 Nov 2022 11:55:47 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 07:00:07 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Pricing of Public Offering

10 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

11 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference

29 Sep 2022 06:30:00 By Nasdaq GlobeNewswire